Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | F13A1 | P00488 | 1/20 | 0.55 |
| ▸ | TGM1 | P22735 | 1/20 | 0.55 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL732934 | 0.90 | TGM2 (0.81) | TGM2LMNAMEN1KMT2ACYP2C19 | |
| SCHEMBL2722983 | 0.85 | TGM2 (0.74) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL2452377 | 0.83 | TGM2 (0.71) | TGM2LMNAMEN1KMT2ACYP2C19 | |
| SCHEMBL124217 | 0.83 | TGM2 (0.71) | TGM2LMNACYP2C19ALDH1A1TSHR | |
| SCHEMBL2724915 | 0.82 | TGM2 (0.70) | TGM2LMNAMEN1KMT2ACYP2C19 | |
| SCHEMBL3298245 | 0.81 | TGM2 (0.69) | TGM2LMNACYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL4927519 | 0.81 | TGM2 (0.69) | TGM2LMNAMEN1KMT2ACYP2C19 | |
| SCHEMBL2723387 | 0.81 | TGM2 (0.69) | TGM2LMNAMEN1KMT2ACYP2C19 | |
| SCHEMBL5071229 | 0.81 | TGM2 (0.69) | TGM2LMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL9179038 | 0.81 | TGM2 (0.69) | TGM2LMNAMEN1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212142-A9 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212142-A9 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20220194924-A1 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-06-23 | — | — | US | disclosed |
| EP-3946288-A1 | SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOL-3-YL-AMINE DERIVATIVES AS SELECTIVE CDK12/13 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2022-02-09 | — | — | EP | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| CN-113727707-A | Substituted 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives as selective CDK12/13 inhibitors | 奥里吉恩发现科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2020202001-A1 | SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOL-3-YL-AMINE DERIVATIVES AS SELECTIVE CDK12/13 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020202001-A1 | SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOL-3-YL-AMINE DERIVATIVES AS SELECTIVE CDK12/13 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-10-08 | — | — | WO | disclosed |
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-27 | — | — | US | disclosed |
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-27 | — | — | US | disclosed |
| CN-109689714-A | Silicone hydrogels comprising N-alkylmethacrylamides and contact lenses made therefrom | 庄臣及庄臣视力保护公司 | 2019-04-26 | — | — | CN | disclosed |
| WO-2018144871-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144869-A1 | COMPOSITONS AND METHODS FOR MODULATING UBA5 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144869-A1 | COMPOSITONS AND METHODS FOR MODULATING UBA5 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144871-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-0490269-B1 | Graft copolymer and process for producing the same | IDEMITSU KOSAN CO (JP) | 1996-02-28 | — | — | EP | disclosed |
| US-5250629-A | Graft polymerization of styrene and ethylenically unsaturated monomer using transition metal catalysts, organoaluminum compounds; films, packaging, automobile parts | IDEMITSU KOSAN CO., LTD. (JP) | 1993-10-05 | — | — | US | disclosed |
| EP-0490269-A1 | Graft copolymer and process for producing the same | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | RTN4, RTN3, RCN1 | TGM2 2492/4885LMNA 2148/4885F13A1 3453/4885 |
| US-20230212142-A9 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | CDK1, CDK12, CDK13 | TGM2 2799/4885LMNA 885/4885F13A1 2125/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | TGM2 3684/4885LMNA 3321/4885F13A1 4169/4885 |
| US-20220194924-A1 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | CDK1, CDK12, CDK13 | TGM2 2799/4885LMNA 885/4885F13A1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.